kwic
cancer
cancer
right
off
ON
290
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for cancer out of >500 occurrences
505522 occurrences (No.25 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to cancer]
505522 occurrences (No.25 in the rank) during 5 years in the PubMed. [cache]
| 290) Together, our study identifies the GPR171/BigLEN axis as a T cell checkpoint pathway that can be modulated for cancer immunotherapy. |
| PMID:34615877 DOI:10.1038/s41467-021-26135-9 |
| 2021 Nature communications |
| * The GPR171 pathway suppresses T cell activation and limits antitumor immunity. |
| - The recently identified G-protein-coupled receptor GPR171 and its ligand BigLEN are thought to regulate food uptake and anxiety. Though GPR171 is commonly used as a T cell signature gene in transcriptomic studies, its potential role in T cell immunity has not been explored. Here we show that GPR171 is transcribed in T cells and its protein expression is induced upon antigen stimulation. The neuropeptide ligand BigLEN interacts with GPR171 to suppress T cell receptor-mediated signalling pathways and to inhibit T cell proliferation. Loss of GPR171 in T cells leads to hyperactivity to antigen stimulation and GPR171 knockout mice exhibit enhanced antitumor immunity. Blockade of GPR171 signalling by an antagonist promotes antitumor T cell immunity and improves immune checkpoint blockade therapies. Together, our study identifies the GPR171/BigLEN axis as a T cell checkpoint pathway that can be modulated for cancer immunotherapy. |
[
right
kwic]
| (1)56 *null* | (18)5  elimination |
(35)3 that |
(52)2 does |
| (2)26 and |
(19)5 types |
(36)3 through |
(53)2 genes |
| (3)25 patients |
(20)4 disparities |
(37)3 who |
(54)2 growth |
| (4)21 cells |
(21)4 treatments |
(38)3 with |
(55)2 incidence |
| (5)13 is |
(22)3 (CRC) |
(39)2 (2) |
(56)2 information |
| (6)12 survivors |
(23)3 (HGSOC) |
(40)2 (BC) |
(57)2 medications |
| (7)12 treatment |
(24)3 (SCLC) |
(41)2 (LC) |
(58)2 mental |
| (8)10 pain |
(25)3 SBRT |
(42)2 (NSCLC) |
(59)2 metastasis |
| (9)10 therapy |
(26)3 are |
(43)2 (TNBC) |
(60)2 mice |
| (10)9 cell |
(27)3 diagnosis |
(44)2 ablation |
(61)2 outcomes |
| (11)9 cells, |
(28)3 for |
(45)2 as |
(62)2 prevention, |
| (12)9 in |
(29)3 has |
(46)2 based |
(63)2 recurrence |
| (13)8 risk |
(30)3 immunotherapy |
(47)2 biomarker |
(64)2 subtype-specific |
| (14)7 screening |
(31)3 or |
(48)2 by |
(65)2 survivors, |
| (15)6 cachexia |
(32)3 patient |
(49)2 cardiovascular |
(66)2 throughout |
| (16)6 care |
(33)3 patients, |
(50)2 continuum, |
(67)2 type |
| (17)6 prevention |
(34)3 research |
(51)2 diagnoses |
add keyword
--- WordNet output for cancer ---